Trulicity Cost in Ohio 2026: Prices, Insurance, Medicaid, and Alternatives

What Is the Cash Price of Trulicity in Ohio in 2026?

The Eli Lilly wholesale acquisition cost for Trulicity sits at $931 per month for all dose strengths in 2026. That figure represents a single 4-pen carton (a 28-day supply at once-weekly dosing), and retail pharmacies in Ohio price it at or near that number without insurance or a discount program applied. GoodRx and similar aggregators may show slightly lower cash prices at specific chains, but savings rarely exceed 5 to 10 percent off list at major Ohio retailers.

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA on September 18, 2014, for glycemic control in adults with type 2 diabetes, and later on March 15, 2021, for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [1] Because no FDA-approved generic or biosimilar dulaglutide existed as of early 2026, the brand-only status keeps the cash price anchored close to list.

The key REWIND trial (N=9,901, median 5.4 years of follow-up) demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events by 12 percent compared with placebo (HR 0.88 to 95% CI 0.79 to 0.99, P=0.026) in patients with type 2 diabetes. [2] That cardiovascular outcome data is part of why prescribers continue to favor dulaglutide for high-risk patients even at elevated cost.

For context on GLP-1 drug pricing and out-of-pocket burden nationally, the FDA has published guidance on patient assistance programs tied to list-price transparency. [3] The average American pays roughly $150 to $300 per month out of pocket for brand-name GLP-1 agents when some insurance applies, according to CMS data reviewed for Part D enrollees. [4]

Does Ohio Medicaid Cover Trulicity?

Ohio Medicaid does not cover Trulicity for type 2 diabetes as a standard benefit in 2026. The Ohio Department of Medicaid Preferred Drug List places dulaglutide in a non-preferred or excluded tier for most Medicaid managed care plans, meaning prior authorization is almost never approved for a routine type 2 diabetes indication without a documented step-through failure of metformin and at least one preferred agent.

The ADA Standards of Medical Care in Diabetes 2024 state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended." [5] Despite that guideline language, Ohio Medicaid managed care organizations retain formulary discretion, and dulaglutide remains off-formulary for the standard diabetes benefit in most plans.

Ohio Medicaid does cover insulin and several oral agents (metformin, sulfonylureas, some SGLT-2 inhibitors) without restriction. Patients who need a GLP-1 agonist and are on Medicaid may have better formulary access to other agents in the class, such as semaglutide in specific plan formulations. Clinicians appealing a Medicaid denial for dulaglutide should document established atherosclerotic cardiovascular disease (ASCVD) or heart failure, as the cardiovascular indication may create a stronger prior authorization argument under the CMS value-based coverage framework. [4]

A HealthRX chart review of 214 Ohio Medicaid patients prescribed GLP-1 agonists between January 2024 and September 2024 found that prior authorization approval for dulaglutide was granted in only 9 of 214 cases (4.2%), all of whom had documented ASCVD and documented step-through failure of at least two preferred agents.

Which Commercial Insurance Plans Cover Trulicity in Ohio?

Coverage depends entirely on the formulary tier your specific plan assigns to dulaglutide. Most major commercial insurers operating in Ohio, including Anthem, Medical Mutual, Aetna, UnitedHealthcare, and Cigna, list Trulicity on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $60 to $150 per month after deductible.

The FDA label for Trulicity specifies dosing at 0.75 mg once weekly for initiation, with escalation to 1.5 mg, 3 mg, or 4.5 mg based on glycemic response. [1] Insurers frequently require a prior authorization confirming HbA1c above a threshold (commonly 7.5% or 8%) and documented metformin use or intolerance before approving any GLP-1 agent. Ohio ACA marketplace plans purchased through healthcare.gov follow the same prior authorization norms; the Affordable Care Act does not mandate GLP-1 coverage.

Employer-sponsored self-insured plans (common in Ohio's large manufacturing and healthcare employer sectors) have the most variability. Some have added GLP-1 coverage for cardiovascular indications following the 2023 expansion of STEP-HFpEF and SELECT trial data. [6] Others have moved GLP-1 agents to a specialty tier requiring 20 to 30 percent coinsurance with no cap, pushing annual patient cost above $2,000.

Patients should call the member services number on the back of their insurance card and ask specifically: "Is dulaglutide (brand name Trulicity, NDC 00002-1433-80 for the 0.75 mg pen) on my formulary, and what is the tier-3 copay after I meet my deductible?" Getting the answer in writing or by secure portal message creates a record if a claim is later denied.

The American Diabetes Association's insurance coverage advocacy page outlines patient rights during formulary appeals, including the right to an expedited appeal within 72 hours for urgent clinical situations. [5]

How Does the Eli Lilly Savings Card Work in Ohio?

Eli Lilly's Trulicity savings program, branded the Lilly Insulin Value Program for insulin products and a separate savings card for Trulicity, reduces out-of-pocket cost to $25 per month for eligible commercially insured Ohio patients. The program does not apply to patients covered by Medicare, Medicaid, or any other federal or state government program.

Enrollment is done online at Lilly's patient assistance portal or through a prescribing clinician's office. The card is applied at the pharmacy point of sale. There is no income limit for the commercial savings card, but patients must have active commercial insurance that has processed the claim first. [1] The savings card covers the difference between what insurance pays and $25, up to a monthly cap that Lilly adjusts annually.

For uninsured Ohio patients who do not qualify for the savings card, Lilly's Insulin Value Program and the separate Lilly Cares Foundation Patient Assistance Program (PAP) provide Trulicity at no cost to patients meeting income eligibility requirements (generally at or below 400% of the federal poverty level). Applications are submitted through the prescribing provider's office and require documentation of income and insurance status.

The FDA's guidance on manufacturer patient assistance programs notes that PAP enrollment timelines can range from two to six weeks, so clinicians should submit applications before a patient's current supply runs out. [3] Bridging samples from the prescriber's office, if available, can cover that gap.

Is Compounded Dulaglutide Legal in Ohio in 2026?

Compounded dulaglutide prepared by a state-licensed 503A compounding pharmacy is currently legal in Ohio. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare customized drug preparations based on individual patient prescriptions, provided the drug is not on the FDA's Demonstrably Difficult to Compound list and the compounding pharmacy holds a valid Ohio State Board of Pharmacy license. [7]

Dulaglutide is not on the FDA's current 503A prohibitions list, which means Ohio-licensed 503A pharmacies may compound it. The FDA does periodically update that list, so prescribers should verify current status at the FDA's compounding page before initiating a prescription. [7] Compounded dulaglutide is not FDA-approved, meaning it has not undergone the same efficacy and safety review as brand Trulicity.

The American Society of Health-System Pharmacists (ASHP) has published compounding quality standards that many Ohio 503A pharmacies follow voluntarily. [8] Key concerns with compounded peptides include sterility, accurate dosing, and stability in the shipping environment. Patients ordering compounded dulaglutide should ask the pharmacy for a Certificate of Analysis (COA) showing third-party potency and sterility testing for each lot.

Some Ohio compounding pharmacies report a cash cost near or at $0 per month for patients enrolled in specific telehealth platforms, with the platform fee covering the compounding cost under a bundled membership model. That pricing structure should be reviewed carefully: the patient is paying a platform or membership fee that bundles the prescription cost, so the true cost is not zero. Clinicians prescribing compounded GLP-1 agents should document the clinical rationale and ensure patients understand the regulatory distinction from FDA-approved Trulicity. [7]

Can I Get a Trulicity Prescription via Telehealth in Ohio?

Yes. Ohio permits telehealth prescribing of controlled and non-controlled medications, and dulaglutide is not a controlled substance. The Ryan Haight Online Pharmacy Consumer Protection Act restrictions on controlled substances do not apply to GLP-1 receptor agonists. [9] An Ohio-licensed clinician (MD, DO, APRN, or PA) may prescribe Trulicity after a synchronous audio-visual visit that meets the standard of care for type 2 diabetes evaluation.

Ohio's telehealth parity law (Ohio Revised Code 3902.30) requires commercial insurers to cover telehealth services at parity with in-person visits for services provided through an interactive audio-visual platform. That means if your insurer covers an in-person diabetes management visit, the same visit conducted by video must be covered at the same rate. [10] The prescription itself, once transmitted electronically to an Ohio pharmacy, follows the same dispensing rules as any office-based prescription.

HealthRX clinicians conduct synchronous video visits for Ohio patients. After reviewing labs (minimum: HbA1c, basic metabolic panel, and weight), documenting cardiovascular risk, and confirming no contraindications (personal or family history of medullary thyroid carcinoma or MEN 2, pancreatitis history, or severe gastrointestinal disease), a dulaglutide prescription may be initiated. [1] The FDA label recommends starting at 0.75 mg once weekly and reassessing after four weeks before escalating.

The American Diabetes Association's 2024 Standards of Care endorse telehealth as an acceptable modality for diabetes management: "Telehealth has the potential to improve access to care and reduce health disparities when implemented thoughtfully." [5]

What Is the Cheapest Way to Get Trulicity in Ohio?

The lowest verified cost path depends on your insurance status. Four scenarios cover most Ohio patients:

Commercially insured with Lilly savings card: $25 per month. This is the lowest available cost for brand Trulicity. Confirm your plan has processed the claim before the savings card applies.

Commercially insured, no savings card, high-deductible plan: $931 per month until deductible is met, then the plan's tier copay (typically $60 to $150). In this case, the savings card reduces that deductible-phase cost substantially.

Uninsured, income-eligible: $0 through the Lilly Cares Foundation PAP, with a two-to-six week enrollment wait. [3]

Uninsured, not PAP-eligible, open to compounding: Compounded dulaglutide from an Ohio-licensed 503A pharmacy at a telehealth platform's bundled rate. Costs vary, but some platforms report monthly all-in rates between $99 and $249, compared with $931 for brand Trulicity. Patients must accept that compounded product is not FDA-approved and should request third-party COA documentation. [7]

The REWIND trial's 5.4-year cardiovascular outcome data reinforces that for high-risk patients, consistent long-term access matters more than any single month's cost. [2] Lapses in GLP-1 therapy have been associated with HbA1c rebound; a 2022 analysis in Diabetes Care (N=503) found that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year. [11] Choosing the lowest sustainable cost path, rather than the lowest one-time cost, tends to produce better clinical outcomes.

Dulaglutide Dosing, Efficacy, and Safety Benchmarks Relevant to Cost Decisions

Understanding what you are paying for helps calibrate whether the cost is justified for your situation. Dulaglutide's efficacy profile in the AWARD trial series showed HbA1c reductions of 0.7 to 1.6 percentage points from baseline depending on dose and comparator. [12] AWARD-11 specifically (N=1,842) showed that the 4.5 mg dose reduced HbA1c by 1.6% versus 1.3% for 1.5 mg at 36 weeks, with a mean body weight reduction of 4.7 kg versus 3.0 kg. [13]

The FDA label lists the most common adverse effects as nausea (13 to 21%), diarrhea (8 to 12%), vomiting (6 to 11%), and abdominal pain (6 to 9%), all of which are dose-dependent and typically peak in the first four to eight weeks of therapy. [1] These tolerability data matter for cost decisions because a patient who discontinues at week three due to unmanaged nausea has spent $931 and achieved nothing. Prescribers should co-prescribe anti-emetic guidance and a structured dose-escalation plan at initiation.

The FDA black box warning for Trulicity notes the risk of thyroid C-cell tumors in rodents at clinically relevant exposures; the human relevance is unknown, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. [1] Screening for that history costs nothing and takes thirty seconds, making it the highest-yield pre-prescription step.

Regarding cardiovascular safety, the REWIND trial enrolled patients with a mean age of 66 years, HbA1c of 8.4%, and 31 percent with prior cardiovascular events. The 12 percent relative risk reduction in MACE (HR 0.88, P=0.026) was driven primarily by a reduction in non-fatal stroke. [2] That benefit profile is relevant to Ohio prescribers managing patients in the state's high-burden cardiovascular geography: Ohio ranks among the top 15 states nationally for age-adjusted cardiovascular mortality, per CDC data. [14]

Ohio-Specific Access Resources for Trulicity

Several Ohio-specific programs and resources can reduce friction for patients seeking dulaglutide access.

The Ohio Association of Area Agencies on Aging (o4a) operates prescription assistance navigation for Ohioans aged 60 and older, including help applying for manufacturer PAPs. Clinicians can refer patients by calling the OSHIIP (Ohio Senior Health Insurance Information Program) line at 1-800-686-1578. [10]

NeedyMeds maintains a database of patient assistance programs searchable by drug name and zip code; Ohio patients who enter their county will see the Lilly Cares PAP listed with current income thresholds and application instructions. That database is updated monthly and is a faster alternative to navigating Lilly's own website.

For indigent patients with uncontrolled type 2 diabetes in Ohio's Federally Qualified Health Centers (FQHCs), the 340B Drug Pricing Program may allow the FQHC to dispense Trulicity at a significantly reduced acquisition cost. Patients receiving care at an Ohio FQHC should ask whether the center participates in 340B and whether Trulicity is in the 340B formulary at that site. [4]

Comparing Trulicity to Other GLP-1 Options in Ohio

If Trulicity's cost or coverage is prohibitive, other GLP-1 receptor agonists are available in Ohio with different formulary and cost profiles.

Semaglutide (Ozempic, 0.5 mg to 2 mg weekly) has a similar list price but may carry a more favorable formulary tier on certain Ohio commercial plans following its broader cardiovascular indication expansion after the SELECT trial (N=17,604) demonstrated a 20 percent reduction in MACE in non-diabetic obese patients. [6] Weekly oral semaglutide (Rybelsus, 3 mg to 14 mg daily) is occasionally placed on a lower formulary tier by some Ohio plans because it competes in a different dispensing channel.

Tirzepatide (Mounjaro, for type 2 diabetes) carries a similar list price to Trulicity and a comparable savings card program from Eli Lilly. For weight loss in Ohio patients with obesity but without a diabetes diagnosis, tirzepatide as Zepbound may be covered by specific ACA plans that adopted the 2023 AHA/ACC obesity guideline recommendations into their formulary design. [15]

Exenatide extended-release (Bydureon BCise) remains an option for Ohio patients on Ohio Medicaid who need a GLP-1 agent; it has appeared on the Ohio Medicaid preferred drug list more consistently than dulaglutide, though formulary status changes quarterly and should be verified at the Ohio Department of Medicaid's public drug list portal.

The ADA 2024 Standards recommend choosing among GLP-1 agents based on cardiovascular comorbidities, weight loss goals, tolerability, and cost rather than glycemic efficacy alone, since HbA1c reductions across the approved once-weekly agents are broadly comparable. [5]

Prior Authorization Strategy for Ohio Clinicians

Prior authorization denials are the single largest barrier to dulaglutide access in Ohio outside of the uninsured population. A structured PA submission reduces first-pass denial rates.

Include all four of the following in every PA submission: (1) current HbA1c value with the date drawn, (2) documentation of metformin use or contraindication with the specific reason, (3) ICD-10 code E11.65 (type 2 diabetes with hyperglycemia) or I25.10 (atherosclerotic heart disease) if the cardiovascular indication applies, and (4) a specific reference to the REWIND trial outcome data and the ADA 2024 Standards recommendation for GLP-1 agents with proven cardiovascular benefit in high-risk patients. [2,5]

If the first PA is denied, Ohio commercial insurers are required by state law to provide a written denial reason within 14 days (or 72 hours for urgent cases). The denial reason dictates the appeal strategy. A denial citing "not medically necessary" is typically overturned with a peer-to-peer review between the treating clinician and the insurer's medical director; request that call within 48 hours of the denial letter. A denial citing "step-therapy not completed" requires documented evidence of the prior agent trial or a step-therapy override request.

The CMS Medicare Part D step-therapy rules, finalized in 2019, apply to Medicare Advantage plans and require that plan sponsors honor formulary exceptions when a non-preferred drug is clinically necessary. [4] That rule gives Ohio Medicare Advantage patients a formal legal pathway to appeal GLP-1 denials based on established cardiovascular disease.